Synthesis and antibacterial activity of N1-(carbazol-3-yl)amidrazones incorporating piperazines and related congeners
-
Ahmad H. Abdullah
, Jalal A. Zahra, Mustafa M. El-Abadelah
, Salim S. Sabri , Monther A. Khanfar , Suzan A. Matar and Wolfgang Voelter
Abstract
A selected set of N1-(4-chloro-9-ethylcarbazol-3-yl)amidrazones (7a–n) has been synthesized by reacting the respective hydrazonoyl chloride 5 derived from 3-amino-9-ethylcarbazole (3), with an appropriate sec-cyclic amine (6a–n) in ethanol in the presence of triethylamine. Unexpectedly, aromatic ring chlorination occurred at C-4 of 3 during its conversion to 6 as evidenced by analytical and spectral data and further confirmed by single crystal X-ray structure determination of the amidrazone 7n. Compounds 7a–n were tested for their in vitro antibacterial activity. Among the tested bacterial strains, methicillin-resistant Staphylococcus aureus was the most susceptible to 7f and Bacillus cereus to 7b both with a minimum inhibitory concentration value of 1.56 µg mL−1. Compounds 7c, 7f, and 7h could be useful as lead structures for further development of new antibacterial agents against Gram-positive and Gram-negative pathogens.
1 Introduction
The carbazole nucleus constitutes the skeleton of a large number of naturally occurring carbazole alkaloids some of which exhibit promising pharmacological activities [1]. Examples, shown in Fig. 1, include murrayanine (isolated from different genera of the Rutaceae family [2–4]) exhibiting antimicrobial properties against human pathogenic fungi [5], clausenal [6], clausenine [7], and clausenol [7], which show inhibitory activity against Gram-positive and Gram-negative bacteria and fungi, glycozolidol [8] endowed with a broad spectrum of antibiotic activity, while glycosinine [9] exhibits anti-HIV-I activity, and carbazomycins B and C are lipoxygenase inhibitors [10]. Besides, several annulated carbazoles and bis-carbazoles were isolated from natural sources [1]. The former class includes pyrido[4,3-b]carbazoles exemplified by ellipticine (isolated from Apocynaceae plants [11, 12]). Ellipticine and its derivatives show promise in the treatment of osteolytic breast cancer metastases, kidney sarcoma, brain tumors, and myeloblastic leukemia [13–15]. The interest in ellipticines for clinical purposes is mainly due to their high efficiency against several types of cancer, limited toxic side effects, and complete lack of hematological toxicity [16].

Selected naturally occurring carbazoles.
On the other hand, N1-aryl(piperazin-1-yl)amidrazones 1, exemplified by 1a (Fig. 2), exhibit substantial antitumor activity against a number of cell lines, especially leukemia, breast, non-small-cell lung, and CNS cancer (IC50 ≈ 4 µm) [17]. The related N1-(flavon-6-yl)amidrazones (2, Fig. 2) were reported to display activity against breast cancer (MCF-7) and leukemia (K562) cell lines with IC50 values of 5.2 and 2.9 µm, respectively for 2a [18].

Cyclic amine-substituted amidrazones.
With the preceding information in mind, we anticipated that a hybrid structure based on amidrazone-carbazole pharmacophores would possess high cytotoxicity and/or antibacterial activity. Accordingly, we report herein on the synthesis and bioassay of a selected set of new N1-(carbazol-3-yl)amidrazones (7a–n; Schemes 1 and 2). Interestingly, it turned out that certain derivatives are highly active against methicillin-resistant Staphylococcus aureus (MRSA) (vide infra).
![Scheme 1: Synthetic route to compound 5 [(i) 18% aq. HCl/NaNO2, 0–4°C; (ii) 50% aq. EtOH, NaOAc, −5 to 0°C].](/document/doi/10.1515/znb-2016-0043/asset/graphic/j_znb-2016-0043_scheme_001.jpg)
Synthetic route to compound 5 [(i) 18% aq. HCl/NaNO2, 0–4°C; (ii) 50% aq. EtOH, NaOAc, −5 to 0°C].

Synthetic route for compounds 7a–n.
2 Results and discussion
2.1 Chemistry
The synthesis of the target N′-(carbazol-3-yl)amidrazones 7a–n (shown in Scheme 2) commenced with the preparation of the appropriate N1-(carbazol-3-yl)hydrazonyl chloride 5 (Scheme 1). Precursor 5 is readily accessible via direct coupling of 3-carbazolediazonium chloride 3A (freshly prepared by diazotization of 3-amino-9H-carbazole) with 3-chloropentane-2,4-dione in aqueous ethanol buffered with sodium acetate. The resulting intermediate azo compound 4 undergoes conversion to the corresponding hydrazone structure 5 via loss of an acetyl group (Japp-Klingemann reaction) [19–22]. Unexpectedly, a chlorine atom has been incorporated at carbon-4 of the carbazole moiety in 5 as evidenced by elemental analysis, high-resolution mass spectra-electrospray ion trap (HRMS-ESI), 1H and 13C NMR spectral data (given in the Experimental section). Thus, a DEPT-90 (distortionless enhancement of polarization transfer using a 90° decoupler pulse) experiment for 5 shows the presence of only six aromatic CH signals, whereas the starting 3-aminocarbazole 3 has seven aromatic CH entities. Additionally, the HRMS spectra of 5 display in the monomeric molecular ion region characteristic isotopic chlorine clusters with a percentage relative abundance ratio of 9:6:1 indicative of the presence of two chlorine atoms in the molecule. Under the prevailing reaction conditions, this process of aromatic ring chlorination is hitherto unprecedented, and for which an explanation requires further practical investigations.
Piperazines and the related sec-cyclic amine congeners 6a–n, acting as nitrogen nucleophiles, are expected to add readily onto N′-(carbazol-3-yl)nitrilimine (the reactive 1,3-dipole generated in situ from its hydrazonoyl chloride 5 in the presence of triethylamine) to produce the respective amidrazone adducts 7a–n (Scheme 2). This mode of nucleophile addition of various nucleophiles onto 1,3-dipolar species is well documented in the literature [23–28], and several related amidrazone adducts were obtained from the reaction of amines with hydrazonoyl chlorides [17, 18, 29, 30].
The newly synthesized amidrazones 7a–n were characterized by MS and NMR spectral data, detailed in the Experimental section. As would be expected, these data reveal that the chlorine atom at C-4 in 5 is retained in the adducts 7a–n and is further confirmed by single crystal X-ray structure determination for 7n as a representative of the series (Fig. 3). In essence, the mass spectra display the correct molecular ion peaks for which the high-resolution (HRMS-ESI) data are in good agreement with the calculated values. The monomeric molecular ion regions are dominated by the characteristic isotopic chlorine clusters (with a relative abundance percent ratio of 3:1). DEPT and 2D (correlation spectroscopy, heteronuclear multiple-quantum coherence, heteronuclear multiple-bond correlation) experiments showed correlations that helped in the 1H and 13C signal assignments to the different carbon atoms and their attached and/or neighboring hydrogen atoms.

Molecular structure of 7n in the crystal and atom numbering scheme adopted. Displacement ellipsoids are drawn at the 30% probability level, hydrogen atoms as spheres with arbitrary radii.
2.2 X-ray structure determination of 7n
An X-ray crystal structure determination was performed to confirm the structure of 7n (Scheme 2) as a representative example of the new synthetic N1-(4-chloro-9-ethylcarbazol-3-yl)amidrazones 7a–n. A summary of the crystal data and numbers pertinent to data collection and refinement is given in Table 1. The molecular structure of 7n in the crystal is shown in Fig. 3.
Crystal data and numbers pertinent to data collection and structure refinement of 7n.
| Empirical formula | C28H29ClN4O |
| Formula weight Mr | 473.01 |
| Temperature, K | 293(2) |
| Wavelength λ, Å | 0.71073 |
| Crystal system | Orthorhombic |
| Space group | P212121 |
| Unit cell dimensions | |
| a, Å | 5.1492(15) |
| b, Å | 13.356(11) |
| c, Å | 35.531(7) |
| Volume, Å3 | 2444(2) |
| Z | 4 |
| Density (calculated), g cm−3 | 1.286 |
| Absorption coefficient μ(MoKα), mm−1 | 0.185 |
| F(000), e | 1000.0 |
| θ range for data collection | 3.25–29.58 |
| Index ranges hkl | −7 ≤ h ≤ 5 |
| −16 ≤ k ≤ 7 | |
| −47 ≤ l ≤ 42 | |
| Reflections collected | 8238 |
| Independent reflections/Rint | 5083/0.057 |
| Completeness to θ = 25.24°, % | 99.4 |
| Data with I > 2σ(I) | 2506 |
| Absorption correction | Semi-empirical from equivalents |
| Refinement method | Full-matrix least squares on F2 |
| Data/restraints/parameters | 5083/0/309 |
| Final R1/wR2a [I > 2 σ(I)] | 0.0726/0.0908 |
| Final R1/wR2a (all data) | 0.1592/0.1183 |
| Flack parameter | 0.01(9) |
| Goodness-of-fit (F2)a | 1.016 |
| Largest difference peak/hole, e Å−3 | 0.19/–0.24 |
aR1 = Σ‖Fo|–|Fc‖/Σ|Fo|; wR2 = [Σw(Fo2 – Fc2)2/Σw(Fo2)2]1/2, w = [σ2(Fo2)+(0.0168P)2]−1, where P = (Max(Fo2, 0)+2Fc2)/3; GoF = S = [Σw(Fo2 – Fc2)2/ (nobs – nparam)]1/2.
2.3 Antibacterial activity
The antimicrobial properties of N1-(4-chloro-9-ethylcarbazol-3-yl)amidrazones 7a–n were evaluated in vitro against an assortment of Gram-positive and Gram-negative bacterial strains, and one fungus Candida albicans. Table 2 shows the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values of seven compounds against four Gram-positive bacterial strains. The following three compounds were also highly active against the indicated Gram-negative bacterial strains: 7a against Salmonella typhimurium (ATCC 14028), 7h against Klebsiella pneumoniae (ATCC 700603), and 7f against K. pneumoniae and Shigella sonnei (ATCC 9290), showing MBC/MIC values of 100/12.5, 6.25/3.125, 100/12.5, and 100/12.5, respectively. The MIC values for the compounds against Gram-positive bacteria ranged from 1.56 to 100 µg mL−1 (Table 2), while the MICs against Gram-negative bacteria were in the range between 12.5 and 100 µg mL−1 (vide supra). Among all of the tested pathogens, MRSA was the most susceptible to 7f, and Bacillus cereus to 7b both with an MIC value of 1.56 µg mL−1 with bactericidal activity against MRSA and bacteriostatic (inhibitory) activity against B. cereus. In this regard, special attention should be devoted to compounds 7c, 7f, and 7m showing high activity against MRSA which is considered as a very important pathogen problematic in nosocomial infections. On the other hand, compound 7b and related congeners, showing high activity against B. cereus (known as a pathogen causing food poisoning), could be considered as candidate preservatives in food industry if they are proven to be non-toxic to humans. Furthermore, compounds 7c, 7f, and 7h could be useful lead structures for further development of new antibacterial agents against Gram-positive and Gram-negative pathogens. However, compounds 7a–n did not exhibit any antifungal properties against C. albicans.
In vitro antibacterial activity of some N1-(carbazol-3-yl)amidrazones (MBC/MIC in µg mL−1)a,b.
| Compound | S. aureus (ATCC 25923) | Clinical strain of Methicillin-resistant S. aureus (MRSA) | B. cereus (ATCC 14579) | C. xerosis (ATTCC 00000) |
|---|---|---|---|---|
| 7b | Tolerant | Tolerant | 12.5/1.56 bacteriostatic | Tolerant |
| 7c | Tolerant | 50/3.125 bacteriostatic | Tolerant | Tolerant |
| 7f | 3.125/3.125 bactericidal | 3.125/1.56 bactericidal | Tolerant | Tolerant |
| 7h | 12.5/6.25 bactericidal | 100/50 bactericidal | 100/25 bacteriostatic | Tolerant |
| 7k | Tolerant | 50/6.25 bacteriostatic | 50/25 bactericidal | 12.5/6.25 bactericidal |
| 7l | Tolerant | 50/25 bactericidal | 100/100 bactericidal | 12.5/6.25 bactericidal |
| 7m | 50/25 bactericidal | 6.25/6.25 bactericidal | Tolerant | Tolerant |
aGentamicin was used as a positive control.
bThe compound is considered to be bactericidal if the MBC is within two dilutions of the MIC (MBC/MIC ≤ 4), and is considered bacteriostatic if the MBC is more than two dilutions higher than MIC (MBC/MIC > 4) [31].
3 Conclusion
A series of novel N1-(4-chloro-9-ethylcarbazol-3-yl)amidrazones of N(4)-substituted piperazines and related congeners were synthesized, characterized, and their antibacterial properties evaluated. The results obtained clearly demonstrate that compounds 7f and 7b exhibit the highest activity against MRSA and B. cereus, respectively. Compound 7b and related congeners, acting against B. cereus, a food-poisoning pathogen, could be considered as a candidate for preservatives in food industry, if non-toxic to humans. Meanwhile, aspects of aromatic ring chlorination of the starting 3-amino-9-ethylcarbazole in 6 n HCl remain, however, unexplored.
4 Experimental section
3-Amino-9H-carbazole, 3-chloropentane-2,4-dione, piperidine, 4-(phenyl)piperidine, morpholine, thiomorpholine, and various N-(substituted)piperazines were purchased from Acros (Geel, Belgium). Melting points (uncorrected) were determined on a Gallenkamp electrothermal melting temperature apparatus (London, UK) in open capillary tubes. 1H, 13C, and 2D NMR spectra were recorded on a 500 MHz spectrometer (Bruker Avance-III, Karlsruhe, Germany) with tetramethylsilane (TMS) as an internal standard. Chemical shifts are expressed in δ units; 1H–1H, 1H–F, and 13C–F coupling constants (J values) are given in hertz. HRMS were measured (in positive or negative ion mode) using an ESI technique by collision-induced dissociation on a Bruker APEX-IV (7 T) instrument (Karlsruhe, Germany). The samples were dissolved in chloroform and infused using a syringe pump with a flow rate of 2 µL min−1. External calibration was conducted using an arginine cluster in a mass range of m/z = 175–871. IR spectra were recorded as KBr disks on a Nicolet Impact-400 FT-IR spectrophotometer (Waltham, MA, USA).
4.1 (E)-N′-(4-Chloro-9-ethyl-9H-carbazol-3-yl)-2-oxopropane-hydrazonoyl chloride (5)
This compound was prepared by the following two-step procedure. Step (i) 9-Ethyl-9H-carbazol-3-amine (3, 2.1 g, 10 mmol) was dissolved in 6 n aqueous hydrochloric acid (20 mL). To this solution, cooled at −5 to 0°C, was dropwise added a solution of sodium nitrite (1.2 g, 17 mmol) in water (2 mL) with efficient stirring. Stirring was continued at 0–4°C for 20–30 min. Step (ii) The fresh diazonium chloride solution, prepared in step (i), was added to a cold solution (−5 to 0°C) of 3-chloropenta-2,4-dione (1.35 g, 10 mmol) and sodium acetate (25 g, 0.3 mol) in 50% aqueous ethanol (20 mL) with vigorous stirring, which was continued at 0–4°C for 20 min. Thereafter, cold water (100 mL) was added to the reaction mixture and stirred for additional 20 min. The resulting precipitate was collected by suction filtration, dried, and purified by column chromatography (using silica as adsorbent and chloroform-hexane (1:1, v/v) as eluent). The title compound was obtained as a yellowish solid. Yield: 1.2 g (34%); m.p. 178–180°C. – IR (KBr): νmax = 3417, 1680, 1523 cm−1. – HRMS ((+)-ESI): m/z = 370.04879 (calcd. 370.04844 for C17H1535Cl2N3ONa, [M+Na]+), 372.04586 (calcd. 372.04549 for C17H1535Cl37ClN3ONa, [M+2+Na]+), 374.04289 (calcd. 374.04254 for C17H1537Cl2N3ONa, [M+4+Na]+). – 1H NMR (500 MHz, CDCl3): δ = 1.46 (t, J = 7.2 Hz, 3H, NCH2CH3), 2.61 (s, 3H, COCH3), 4.40 (q, J = 7.2 Hz, 2H, NCH2CH3), 7.30 (pseudo-t, J = 7.5 Hz, 1H, 6-H), 7.36 (d, J = 8.8 Hz, 1H, 1-H), 7.43 (d, J = 8.2 Hz, 8-H), 7.55 (pseudo-t, J = 7.6 Hz, 1H, 7-H), 7.70 (d, J = 8.8 Hz, 1H, 2-H), 8.59 (d, J = 7.9 Hz, 1H, 5-H), 9.05 (s, 1H, N–H) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.8 (NCH2CH3), 25.3 (COCH3), 37.8 (NCH2CH3), 108.0 (C-1), 108.6 (C-8), 113.5 (C-2), 114.1 (C-4), 119.3 (C-6), 120.1 (C-4a), 121.7 (C-4b), 123.1 (C-5), 125.8 (N–C=N), 126.6 (C-7), 130.3 (C-3), 137.0 (C-9a), 140.4 (C-8a), 188.2 (COCH3) ppm. – C17H15Cl2N3O (348.23): calcd. C 58.63, H 4.34, Cl 20.36, N 12.07; found C 58.45, H 4.19, Cl 20.16, N 11.88.
4.2 General procedure for the preparation of amidrazones 7a–n
To a stirred cold suspension (−5 to 0°C) of the hydrazonoyl chloride (5) (0.20 g, 0.57 mmol) in ethanol (20 mL) in a dark flask was added triethylamine (2 mL), followed by the addition of the particular cyclic secondary amine 6a–n (2.8 mmol). Stirring was continued at −5 to 0°C for 2–4 h, and then at ambient temperature for 10–12 h. Thereafter, the reaction mixture was diluted with water (100 mL) and stirred for 10 min. The resulting crude solid product was collected by suction filtration, washed with cold water, and dried.
4.2.1 1-[2-(4-Chloro-9-ethyl-9H-carbazol-3-yl)hydrazono]-1-(piperidin-1′-yl)propan-2-one (7a)
Yield: 0.20 g (87%); m.p. 119–121°C. – IR (KBr): νmax = 3419, 1667, 1505 cm−1. – HRMS ((+)-ESI): m/z = 419.16068 (calcd. 419.16091 for C22H2535ClN4NaO, [M+Na]+), 421.15776 (calcd. 421.15880 for C22H2537ClN4NaO, [M+2+Na]+). – 1H NMR (500 MHz, CDCl3): δ = 1.46 (t, J = 7.2 Hz, 3H, NCH2CH3), 1.69 (m, 2H, H2-4′), 1.75 (m, 4H, 3′-H2/5′-H2), 2.49 (s, 3H, COCH3), 3.08 (t, J = 5.2 Hz, 4H, 2′-H2/6′ - H2), 4.40 (q, J = 7.2 Hz, 2H, NCH2CH3), 7.29 (pseudo-t, J = 7.4 Hz, 1H, 6-H), 7.38 (d, J = 8.9 Hz, 1H, 1-H), 7.44 (d, J = 8.3 Hz, 1H, 8-H), 7.54 (pseudo-t, J = 7.4 Hz, 1H, 7- H), 7.85 (d, J = 8.9 Hz, 1H, 2-H), 8.63 (d, J = 7.9 Hz, 1H, 5-H), 9.83 (s, 1H, N–H) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.8 (NCH2CH3), 24.3 (C-4`), 25.8 (COCH3), 27.1 (C-3′/C-5′), 37.7 (NCH2CH3), 49.2 (C-2′/C-6′), 107.9 (C-1), 108.5 (C-8), 113.4 (C-4), 113.5 (C-2), 119.0 (C-6), 120.1 (C-4a), 121.9 (C-4b), 123.1 (C-5), 126.2 (C-7), 132.2 (C-3), 136.2 (C-9a), 140.4 (C-8a), 145.4 (N–C=N), 195.0 (COCH3) ppm.
4.2.2 1-[2-(4-Chloro-9-ethyl-9H-carbazol-3-yl)hydrazono]-1-morpholinopropan-2-one (7b)
Yield: 0.22 g (96%); m.p. 172–174°C. – IR (KBr): νmax 3414, 1657, 1524 cm−1. –HRMS ((+)-ESI): m/z = 421.14006 (calcd. 421.14017 for C21H2335ClN4NaO2, [M+Na]+), 423.13721 (calcd. 423.13804 for C21H2337ClN4NaO2, [M+2+Na]+). – 1H NMR (500 MHz, CDCl3): δ = 1.46 (t, J = 7.2 Hz, 3H, NCH2CH3), 2.51 (s, 3H, COCH3), 3.18 (m, 4H, 2′-H2/6′-H2), 3.91 (t, J = 4.6 Hz, 4H, 3′-H2/5′-H2), 4.40 (q, J = 7.2 Hz, 2H, NCH2CH3), 7.31 (pseudo-t, J = 7.6 Hz, 1H, 6-H), 7.39 (d, J = 8.8 Hz, 1H, 1-H), 7.45 (d, J = 8.3 Hz, 1H, 8-H), 7.55 (pseudo-t, J = 7.6 Hz,1H, 7-H), 7.85 (d, J = 8.8 Hz, 1H, 2-H), 8.63 (d, J = 8.0 Hz, 1H, 5-H), 9.93 (s, 1H, N–H) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.8 (NCH2CH3), 25.7 (COCH3), 37.8 (NCH2CH3), 48.2 (C-2′/C-6′), 68.0 (C-3′/C-5′), 108.0 (C-1), 108.6 (C-8), 113.4 (C-2), 113.5 (C-4), 119.1 (C-6), 120.1 (C-4a), 121.8 (C-4b), 123.1 (C-5), 126.4 (C-7), 131.7 (C-3), 136.4 (C-9a), 140.4 (C-8a), 143.4 (N–C=N), 194.6 (COCH3) ppm.
4.2.3 1-[2-(4-Chloro-9-ethyl-9H-carbazol-3-yl)hydrazono]-1-thiomorpholino-propan-2-one (7c)
Yield: 0.23 g (96%); m.p. 148–150°C. – IR (KBr): νmax = 3414, 1661, 1525 cm−1. – HRMS ((+)-ESI): m/z = 437.11765 (calcd. 437.11733 for C21H2335ClN4NaOS, [M+Na]+), 439.11456 (calcd. 439.11495 for C21H2337ClN4NaOS, [M+2+Na]+). – 1H NMR (500 MHz, CDCl3): δ = 1.46 (t, J = 7.2 Hz, 3H, NCH2CH3), 2.50 (s, 3H, COCH3), 2.87 (m, 4H, 3′-H2/5′-H2), 3.37 (m, 4H, 2′-H2, 6′-H2), 4.40 (q, J = 7.2 Hz, 2H, NCH2CH3), 7.30 (pseudo-t, J = 7.7 Hz, 1H, 6-H), 7.39 (d, J = 8.8 Hz, 1H, 1-H), 7.45 (d, J = 8.3 Hz, 1H, 8-H), 7.55 (pseudo-t, J = 7.7 Hz,1H, 7-H), 7.85 (d, J = 8.8 Hz, 1H, 2-H), 8.63 (d, J = 7.9Hz, 1H, 5-H), 9.77 (s, 1H, N–H) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.8 (NCH2CH3), 25.6 (COCH3), 29.1 (C-3′/C-5′), 37.8 (NCH2CH3), 50.4 (C-2′/C-6′), 108.0 (C-1), 108.6 (C-8), 113.4 (C-2), 113.5 (C-4), 119.1 (C-6), 120.1 (C-4a), 121.8 (C-4b), 123.1 (C-5), 126.4 (C-7), 131.7 (C-3), 136.4 (C-9a), 140.4 (C-8a), 144.6 (N–C=N), 194.6 (COCH3) ppm.
4.2.4 1-[2-(4-Chloro-9-ethyl-9H-carbazol-3-yl)hydrazono]-1-(4′-methylpiperazin-1′-yl)propan-2-one (7d)
Yield: 0.23 g (96%); m.p. 155–158°C. (decomp.) – IR (KBr): νmax = 3414, 1657, 1525 cm−1. – HRMS ((+)-ESI): m/z = 412.18955 (calcd. 412.18986 for C22H2735ClN5O, [M+H]+), 414.18675 (calcd. 414.18776 for C22H2737ClN5O, [M+2+H]+), 434.17194 (calcd. 434.17181 for C22H2635ClN5O, [M+Na]+), 436.16905 (calcd. 436.16971 for C22H2637ClN5O, [M+2+Na]+). – 1H NMR (500 MHz, CDCl3): δ = 1.46 (t, J = 7.2 Hz, 3H, NCH2CH3), 2.42 (s, 3H, NCH3), 2.50 (s, 3H, COCH3), 2.62 (m, 4H, 3′-H2/5′-H2), 3.20 (m, 4H, 2′-H2/6′-H2), 4.40 (q, J = 7.2 Hz, 2H, NCH2CH3), 7.29 (pseudo-t, J = 7.6 Hz, 1H, 6-H), 7.38 (d, J = 8.8 Hz, 1H, 1-H), 7.45 (d, J = 8.2 Hz, 1H, 8-H), 7.54 (pseudo-t, J = 7.6 Hz,1H, 7-H), 7.84 (d, J = 8.8 Hz, 1H, 2-H), 8.63 (d, J = 8.0 Hz, 1H, 5-H), 9.80 (s,1H, N–H) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.8 (NCH2CH3), 25.7 (COCH3), 37.7 (NCH2CH3), 46.5 (NCH3), 47.8 (C-2′/C-6′), 56.2 (C-3′/C-5′), 107.9 (C-1), 108.5 (C-8), 113.4 (C-4), 113.5 (C-2), 119.0 (C-6), 120.1 (C-4a), 121.9 (C-4b), 123.1 (C-5), 126.3 (C-7), 132.0 (C-3), 136.3 (C-9a), 140.4 (C-8a), 144.1 (N–C=N), 194.7 (COCH3) ppm.
4.2.5 1-[2-(4-Chloro-9-ethyl-9H-carbazol-3-yl)hydrazono]-1-(4′-ethylpiperazin-1′-yl)propan-2-one (7e)
Yield: 0.22 g (92%); m.p. 138–140°C. – IR (KBr): νmax = 3414, 1661, 1526 cm−1. – HRMS ((+)-ESI): m/z = 426.20475 (calcd. 426.20551 for C23H2935ClN5O, [M+H]+), 428.2019 (calcd. 428.20348 for C23H2937ClN5O, [M+2+H]+). – 1H NMR (500 MHz, CDCl3): δ = 1.18 (t, J = 7.2 Hz, 3H, N(4′)-CH2CH3), 1.46 (t, J = 7.2 Hz, 3H, N(9)-CH2CH3), 2.50 (s, 3H, COCH3), 2.55 (q, J = 7.2 Hz, 2H, N(4′)-CH2CH3), 2.67 (m, 4H, 3′-H2/5′-H2), 3.21 (m, 4H, 2′-H2/6′-H2), 4.40 (q, J = 7.2 Hz, 2H, N(9)-CH2CH3), 7.30 (pseudo-t, J = 7.6 Hz, 1H, 6-H), 7.39 (d, J = 8.8 Hz, 1H, 1-H), 7.45 (d, J = 8.3 Hz, 1H, 8-H), 7.55 (pseudo-t, J = 7.9 Hz,1H, 7-H), 7.85 (d, J = 8.8, 1H, 2-H), 8.63 (d, J = 7.9 Hz, 1H, 5-H), 9.80 (s,1H, N–H) ppm. –13C NMR (125 MHz, CDCl3): δ = 12.0 (N(4′)-CH2CH3), 13.8 (N(9)-CH2CH3), 25.7 (COCH3), 37.7 (N(9)-CH2CH3), 47.8 (C-2′/C-6′), 52.6 (N(4′)-CH2CH3), 54.0 (C-3′/C-5′), 108.0 (C-1), 108.5 (C-8), 113.4 (C-4), 113.5 (C-2), 119.0 (C-6), 120.1 (C-4a), 121.9 (C-4b), 123.1 (C-5), 126.3 (C-7), 132.0 (C-3), 136.3 (C-9a), 140.4 (C-8a), 144.2 (N–C=N), 194.7 (COCH3) ppm.
4.2.6 1-[2-(4-Chloro-9-ethyl-9H-carbazol-3-yl)hydrazono]-1-(4′-(2-hydroxyethyl)piperazin-1′-yl)propan-2-one (7f)
Yield: 0.23 g (96%); m.p. 205–207°C. – IR (KBr): νmax = 3699, 3410, 1662, 1512 cm−1. – HRMS ((+)-ESI): m/z = 442.20023 (calcd. 442.20043 for C23H2935ClN5O2, [M+H]+), 444.19718 (calcd. 444.19844 for C23H2937ClN5O2, [M+2+H]+). – 1H NMR (500 MHz, CDCl3): δ = 1.46 (t, J = 7.0 Hz, 3H, NCH2CH3), 2.51 (s, 3H, COCH3), 2.67 (br s, 2H, NCH2CH2OH), 2.74 (m, 4H, 3′-H2/5′-H2), 2.92 (br s, 1H, NCH2CH2OH), 3.20 (m, 4H, 2′-H2/6′-H2), 3.70 (m, 2H, NCH2CH2OH), 4.39 (q, J = 7.0 Hz, 2H, NCH2CH3), 7.30 (pseudo-t, J = 7.4 Hz, 1H, 6-H), 7.39 (d, J = 8.7 Hz, 1H, 1-H), 7.45 (d, J = 8.2 Hz, 1H, 8-H), 7.55 (pseudo-t, J = 7.4 Hz,1H, 7-H), 7.85 (d, J = 8.7, 1H, 2-H), 8.63 (d, J = 7.9 Hz, 1H, 5-H), 9.81 (s, 1H, N–H) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.8 (NCH2CH3), 25.7 (COCH3), 37.7 (NCH2CH3), 47.9 (C-2′/C-6′), 54.0 (C-3′/C-5′), 57.7 (NCH2CH2OH), 59.5 (NCH2CH2OH), 108.0 (C-1), 108.6 (C-8), 113.4 (C-4), 113.5 (C-2), 119.0 (C-6), 120.1 (C-4a), 121.9 (C-4b), 123.1 (C-5), 126.3 (C-7), 131.9 (C-3), 136.3 (C-9a), 140.4 (C-8a), 144.0 (N–C=N), 194.7 (COCH3) ppm.
4.2.7 Ethyl 4′-[1-(2-(4-chloro-9-ethyl-9H-carbazol-3-yl))hydrazono]-2-(oxopropyl)piperazine-1-carboxylate (7g)
Yield: 0.26 g (94%); m.p. 168–170°C. – IR (KBr): νmax = 3419, 1701,1667, 1506 cm−1. – HRMS ((–)-ESI): m/z = 468.18115 (calcd. 468.18079 for C24H2735ClN5O3, [M+H]−), 470.17639 (calcd. 470.17890 for C24H2737ClN5O3, [M+2+H]−). – 1H NMR (500 MHz, CDCl3): δ = 1.33 (t, J = 7.2 Hz, 3H, NCO2CH2CH3), 1.46 (t, J = 7.1 Hz, 3H, NCH2CH3), 2.50 (s, 3H, COCH3), 3.13 (m, 4H, 3′-H2/5′-H2), 3.70 (m, 4H, 2′-H2/6′-H2), 4.22 (q, J = 7.2 Hz, 2H, NCO2CH2CH3), 4.40 (q, J = 7.1 Hz, 2H, NCH2CH3), 7.30 (pseudo-t, J = 7.4 Hz, 1H, 6-H), 7.39 (d, J = 8.8 Hz, 1H, 1-H), 7.45 (d, J = 8.2 Hz, 8-H), 7.55 (pseudo-t, J = 7.4 Hz,1H, 7-H), 7.84 (d, J = 8.8 Hz, 1H, 2-H), 8.62 (d, J = 7.9, 1H, 5-H), 9.87 (s,1H, N–H) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.8 (NCH2CH3), 14.7 (NCO2CH2CH3), 25.3 (COCH3), 37.8 (NCH2CH3), 47.8 (C-2′/C-6′, C-3′/C-5′), 61.5 (NCO2CH2CH3), 108.0 (C-1), 108.6 (C-8), 113.4 (C-2), 113.5 (C-4), 119.1 (C-6), 120.1 (C-4a), 121.9 (C-4b), 123.1 (C-5), 126.4 (C-7), 131.6 (C-3), 136.4 (C-9a), 140.4 (C-8a), 143.6 (N–C=N), 155.6 (NCO2CH2CH3), 194.6 (COCH3) ppm.
4.2.8 4′-[1-(2-(4-Chloro-9-ethyl-9H-carbazol-3-yl))hydrazono]-2-(oxopropyl)piperazine-1-carbaldehyde (7h)
Yield: 0.20 g (83%); m.p. 98–100°C. – IR (KBr): νmax = 3419, 1674, 1509 cm−1. – HRMS ((+)-ESI): m/z = 424.15435 (calcd. 424.15458 for C22H2335ClN5O2, [M+H]+), 426.15113 (calcd. 426.15251 for C22H2337ClN5O2, [M+2+H]+), 448.15116 (calcd. 448.15107 for C22H2435ClN5NaO2, [M+Na]+), 450.14786 (calcd. 450.14901 for C22H2437ClN5NaO2, [M+2+Na]+). – 1H NMR (500 MHz, CDCl3): δ = 1.45 (t, J = 7.2 Hz, 3H, NCH2CH3), 2.52 (s, 3H, COCH3), [3.12 (t, J = 4.9 Hz, 2H) and 3.13 (m, 2H)(2′-H2/6′-H2)], [(3.57 (t, J = 4.9 Hz, 2H) and 3.77 (m, 2H)(3′-H2/5′-H2], 4.40 (q, J = 7.2 Hz, 2H, NCH2CH3), 7.31 (pseudo-t, J = 7.9 Hz, 1H, H-6), 7.40 (d, J = 8.8 Hz, 1H, 1-H), 7.45 (d, J = 8.2 Hz, 1H, 8-H), 7.55 (ddd, J = 8.2, 7.2, 1.0 Hz, 1H, 7-H), 7.66 (d, J = 8.8 Hz, 1H, 2-H), 8.18 (s, 1H, N(4′)-CHO), 8.61 (d, J = 7.9 Hz, 1H, 5-H), 9.86 (s, 1H, N–H) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.8 (NCH2CH3), 25.6 (COCH3), 37.8 (NCH2CH3), 41.1 and 46.8 (C-5′/C-3′), 47.4 and 48.6 (C-6′/C-2′), 108.0 (C-1), 108.6 (C-8), 113.5 (C-2), 113.6 (C-4), 119.1 (C-6), 120.1 (C-4a), 121.8 (C-4b), 123.1 (C-5), 126.4 (C-7), 131.4 (C-3), 136.5 (C-9a), 140.4 (C-8a), 143.1 (N–C=N), 161.0 (N(C4′)-CHO), 194.6 (COCH3) ppm.
4.2.9 1-[2-(4-Chloro-9-ethyl-9H-carbazol-3-yl)hydrazono]-1-(4′-phenylpiperazin-1″-yl)propan-2-one (7i)
Yield: 0.26 g (96%); m.p. 197–199°C. – IR (KBr): νmax = 3431, 1671, 1500 cm−1. – HRMS ((+)-ESI): m/z = 474.20604 (calcd. 474.20551 for C27H2935ClN5O, [M+H]+), 476.20315 (calcd. 476.20376 for C27H2937ClN5O, [M+2+H]+), 496.18832 (calcd. 496.18746 for C27H2835ClN5NaO, [M+Na]+), 498.18557 calcd. 498.18571 for C27H2837ClN5NaO, [M+2+Na]+). – 1H NMR (500 MHz, CDCl3): δ = 1.47 (t, J = 7.0 Hz, 3H, NCH2CH3), 2.54 (s, 3H, COCH3), 3.35 (m, 4H, 3′-H2/5′-H2), 3.40 (m, 4H, 2′-H2/6′-H2), 4.40 (q, J = 7.0 Hz, 2H, NCH2CH3), 6.95 (t, J = 7.3 Hz, 1H, 4″-H), 7.04 (d, J = 8.0 Hz, 2H, 2″-H/6″-H), 7.30 (pseudo-t, J = 7.3 Hz, 1H, 6-H), 7.35 (pseudo-t, J = 7.3 Hz, 2H, 3″-H/5″-H)), 7.40 (d, J = 8.8 Hz, 1H, 1-H), 7.45 (d, J = 8.3 Hz, 1H, 8-H), 7.55 (pseudo-t, J = 7.7 Hz, 1H, 7-H), 7.87 (d, J = 8.8 Hz, 1H, 2-H), 8.62 (d, J = 8.0 Hz, 1H, 5-H), 9.89 (s, 1H, N–H) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.8 (NCH2CH3), 25.7 (COCH3), 37.8 (NCH2CH3), 48.1 (C-2′/C-6′), 50.5 (C-3′/C-5′), 108.0 (C-1), 108.5 (C-8), 113.5 (C-2), 113.6 (C-4), 116.3 (C-2″/C-6″), 119.1 (C-6), 120.0 (C-4″), 120.1 (C-4a), 121.9 (C-4b), 123.1 (C-5), 126.3 (C-7), 129.2 (C-3″, C-5″), 131.9 (C-3), 136.4 (C-9a), 140.4 (C-8a), 143.9 (N–C=N), 151.5 (C-1″), 194.8 (COCH3) ppm.
4.2.10 1-[2-(4-Chloro-9-ethyl-9H-carbazol-3-yl)hydrazono]-1-[4′-(4″-fluorophenyl)piperazin-1′-yl]propan-2-one (7j)
Yield: 0.27 g (96%); m.p. 187–189°C. – IR (KBr): νmax = 3445, 1670, 1506 cm−1. – HRMS ((+)-ESI): m/z = 492.19570 (calcd. 492.19609 for C27H2835ClFN5O, [M+H]+), 494.19275 (calcd. 494.19434 for C27H2837ClFN5O, [M+2+H]+). – 1H NMR (500 MHz, CDCl3): δ = 1.46 (t, J = 7.2 Hz, 3H, NCH2CH3), 2.54 (s, 3H, COCH3), 3.31 (m, 4H, 3′-H2/5′-H2), 3.32 (m, 4H, 2′-H2/6′-H2), 4.40 (q, J = 7.2 Hz, 2H, NCH2CH3), 6.97 (m, 2H, 2″-H/6″-H), 7.03 (pseudo-t, J = 6.7 Hz, 2H, 3″-H/5″-H), 7.29 (ddd, J = 7.9, 7.1, 3.5 Hz, 1H, 6-H), 7.39 (d, J = 8.8 Hz, 1H, 1-H), 7.45 (d, J = 8.2 Hz, 1H, 8-H), 7.55 (ddd, J = 8.2, 7.1, 1.2 Hz,1H, 7-H), 7.86 (d, J = 8.8 Hz, 1H, 2-H), 8.61 (d, J = 7.9 Hz, 1H, 5-H), 9.87 (s, 1H, N–H) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.8 (NCH2CH3), 25.7 (COCH3), 37.7 (NCH2CH3), 48.0 (C-2′/C-6′), 51.5 (C-3′/C-5′), 108.0 (C-1), 108.6 (C-8), 113.4 (C-2), 113.5 (C-4), 115.6 (d, 2JC-F = 21.9 Hz, C-3″/C-5″), 118.1 (d, 3JC-F = 7.6 Hz, C-2″/C-6″), 119.1 (C-6), 120.1 (C-4a), 121.8 (C-4b), 123.1 (C-5), 126.3 (C-7), 131.8 (C-3), 136.4 (C-9a), 140.4 (C-8a), 143.8 (N–C=N), 148.2 (d, 4JC-F = 1.9 Hz, C-1″), 157.3 (d, 1JC-F = 238 Hz, C-4″), 194.8 (COCH3) ppm.
4.2.11 1-[2-(4-Chloro-9-ethyl-9H-carbazol-3-yl)hydrazono]-1-[4′-(4″-hydroxyphenyl)piperazine-1″-yl]propan-2-one (7k)
Yield: 0.25 g (89%); m.p. 190–192°C. – IR (KBr): νmax = 3447, 1655, 1509 cm−1. – HRMS ((+)-ESI): m/z = 490.20019 (calcd. 490.20043 for C27H2935ClN5O2, [M+H]+), 492.19716 (calcd. 492.19871 for C27H2937ClN5O2, [M+2+H]+). – 1H NMR (500 MHz, CDCl3): δ = 1.45 (t, J = 7.2 Hz, 3H, NCH2CH3), 2.53 (s, 3H, COCH3), 3.27 (m, 4H, 3′-H2/5′-H2), 3.33 (m, 4H, 2′-H2/6′-H2), 4.40 (q, J = 7.2 Hz, 2H, NCH2CH3), 6.85 (d, J = 8.6 Hz, 2H, 3″-H/5″-H)), 6.96 (d, J = 8.6 Hz, 2H, 2″-H/6″-H), 7.29 (pseudo-t, J = 8.0 Hz, 1H, 6-H), 7.39 (d, J = 8.8 Hz, 1H, 1-H), 7.44 (d, J = 8.2 Hz, 1H, 8-H), 7.54 (pseudo-t, J = 8.2 Hz,1H, 7-H), 7.86 (d, J = 8.8 Hz, 1H, 2-H), 8.61 (d, J = 8.0 Hz, 1H, 5-H), 9.87 (s, 1H, N–H), 12.84 (s, 1H, -OH) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.8 (NCH2CH3), 25.7 (COCH3), 37.8 (NCH2CH3), 48.1 (C-2′/C-6′), 52.0 (C-3′/C-5′), 108.0 (C-1), 108.5 (C-8), 113.5 (C-2), 113.6 (C-4), 115.9 (C-3″/C-5″), 118.7 (C-2″/C-6″), 119.1 (C-6), 120.1 (C-4a), 121.9 (C-4b), 123.1 (C-5), 126.3 (C-7), 131.9 (C-3), 136.4 (C-9a), 140.4 (C-8a), 143.9 (N–C=N), 145.9 (C-1″), 150.0 (C-4″), 194.9 (COCH3) ppm.
4.2.12 1-[2-(4-Chloro-9-ethyl-9H-carbazol-3-yl)hydrazono]-1-[4′-(pyridin-2″-yl)piperazin-1-yl]propan-2-one (7l)
Yield: 0.25 g (93%); m.p. 183–185°C. – IR (KBr): νmax = 3412, 1672, 1592 cm−1. – HRMS ((+)-ESI): m/z = 475.20045 (calcd. 475.20076 for C26H2835ClN6O, [M+H]+), 477.39097 (calcd. 477.19894 for C26H2837ClN6O, [M+2+H]+). – 1H NMR (500 MHz, CDCl3): δ = 1.46 (t, J = 7.3 Hz, 3H, NCH2CH3), 2.54 (s, 3H, COCH3), 3.29 (t, J = 4.5 Hz, 4H, 3′-H2/5′-H2), 3.75 (m, 4H, 2′-H2/6′-H2), 4.39 (q, J = 7.3 Hz, 2H, NCH2CH3), 6.70 (dd, J = 7.0, 5.1 Hz, 1H, 5″-H), 6.75 (d, J = 8.6 Hz, 1H, 3″-H), 7.29 (pseudo-t, J = 8.0 Hz, 1H, 6-H), 7.39 (d, J = 8.8 Hz, 1H, 1-H), 7.44 (d, J = 8.2 Hz, 1H, 8-H), 7.54 (m, 2H, 7-H and 4″-H),7.86 (d, J = 8.8 Hz, 1H, 2-H), 8.27 (dd, J = 5.1, 1.6 Hz, 1H, 6″-H), 8.60 (d, J = 7.9 Hz, 1H, 5-H), 9.92 (s, 1H, N–H) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.8 (NCH2CH3), 25.7 (COCH3), 37.7 (NCH2CH3), 46.1 (C-2′/C-6′), 47.8 (C-3′/C-5′), 107.4 (C-3″), 108.0 (C-1), 108.5 (C-8), 113.4 (C-2), 113.5 (C-4), 113.6 (C-5″), 119.0 (C-6), 120.1 (C-4a), 121.8 (C-4b), 123.1 (C-5), 126.3 (C-7), 131.8 (C-3), 136.4 (C-9a), 137.6 (C-4″), 140.4 (C-8a), 143.8 (N–C=N), 148.0 (C-6″), 159.6 (C-2″), 194.7 (COCH3) ppm.
4.2.13 1-[2-(4-Chloro-9-ethyl-9H-carbazol-3-yl)hydrazono]-1-[4′-(pyrimidin-2″-yl)piperazin-1-yl]propan-2-one (7m)
Yield: 0.25 g (92%); m.p. 174–176°C, – IR (KBr): νmax = 3414, 1670, 1582 cm−1. – HRMS ((+)ESI): m/z = 476.19653 (calcd. 476.19601 for C25H2735ClN7O, [M+H]+), 478.19355 (calcd. 478.19413 for C25H2737ClN7O, [M+2+H]+). – 1H NMR (500 MHz, CDCl3): δ = 1.46 (t, J = 7.3 Hz, 3H, NCH2CH3), 2.52 (s, 3H, COCH3), 3.23 (t, J = 4.7 Hz, 4H, 3′-H2/5′-H2), 4.05 (m, 4H, 2′-H2/6′-H2), 4.38 (q, J = 7.3 Hz, 2H, NCH2CH3), 6.56 (t, J = 4.8Hz, 1H, 5″-H), 7.29 (ddd, J = 8.0, 7.1, 1.0, Hz, 1H, 6-H), 7.38 (d, J = 8.8 Hz, 1H, 1-H), 7.43 (d, J = 8.2 Hz, 1H, 8-H), 7.54 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H, 7-H), 7.86 (d, J = 8.8 Hz, 1H, 2-H), 8.38 (d, J = 4.8 Hz, 2H, 6″-H/4″-H), 8.61 (d, J = 8.0 Hz, 1H, 5-H), 9.96 (s, 1H, N–H) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.8 (NCH2CH3), 25.7 (COCH3), 37.7 (NCH2CH3), 44.9 (C-2′/C-6′), 47.9 (C-3′/C-5′), 108.0 (C-1), 108.5 (C-8), 110.1 (C-5″), 113.5 (C-2), 113.6 (C-4), 119.0 (C-6), 120.1 (C-4a), 121.8 (C-4b), 123.1 (C-5), 126.3 (C-7), 131.7 (C-3), 136.4 (C-9a), 140.4 (C-8a), 143.9 (N–C=N), 157.8 (C-6″/C-4″), 161.8 (C-2″), 194.7 (COCH3) ppm.
4.2.14 1-[2-(4-Chloro-9-ethyl-9H-carbazol-3-yl)hydrazono]-1-(4′-phenylpiperidin-1″-yl)propan-2-one (7n)
Yield: 0.26 g (96%); m.p. 168–170°C. – IR (KBr): νmax = 3404, 1665, 1534 cm−1. – HRMS ((+)-ESI): m/z = 495.19274 (calcd. 495.19221 for C28H2935ClN4NaO, [M+Na]+), 497.18963 (calcd. 497.19053 for C28H2937ClN4NaO, [M+2+Na]+). – 1H NMR (500 MHz, CDCl3): δ = 1.46 (t, J = 7.2 Hz, 3H, NCH2CH3), [1.45 (m, 2H), 2.05 (m, 2H), 3′-H2/5′-H2)], 2.55 (s, 3H, COCH3), 2.82 (m, 1H, 4′-H), [3.06 (m, 2H), 3.49 (m, 2H), (2′-H2/6′-H2)], 4.40 (q, J = 7.2 Hz, 2H, NCH2CH3), 7.32 (pseudo-t, J = 7.4 Hz, 1H, 6-H), 7.37 (m, 2H, 3″-H/5"-H), 7.41 (d, J = 8.8 Hz, 1H, 1-H), 7.43 (m, 2H, 2″-H/5"-H), 7.46 (d, J = 8.2 Hz, 1H, H-8), 7.56 (pseudo-t, 2H, H-7 and H-4″), 7.89 (d, J = 8.8 Hz, 1H, 2-H), 8.67 (d, J = 7.9 Hz, 1H, 5-H), 9.90 (s, 1H, N–H) ppm. – 13C NMR (125 MHz, CDCl3): δ = 13.8 (NCH2CH3), 25.7 (COCH3), 34.6 (C-3′/C-5′), 37.8 (NCH2CH3), 42.3 (C-4′), 49.0 (C-2′/C-6′), 108.0 (C-1), 108.5 (C-8), 113.4 (C-2), 113.5 (C-4), 119.0 (C-6), 120.1 (C-4a), 121.9 (C-4b), 123.1 (C-5), 126.3 (C-7 and C-4″), 126.9 (C-3″/C-5″), 128.6 (C-2″/C-6″), 132.1 (C-3), 136.3 (C-9a), 140.4 (C-8a), 145.4 (N–C=N), 146.3 (C-1″), 195.0 (COCH3) ppm.
4.3 Antibacterial activity
The antibacterial activity of compounds 7a–c, 7f, 7h, and 7k–m was determined by the standard broth dilution assay [32] using 96-well microtiter plates. Stock solutions of the compounds in 80% methanol were serially diluted in 100 mL volumes of Mueller-Hinton broth (Oxoid) to obtain known concentrations of the compound per milliliter. To each well was added 10 µL of a 1/100 dilution of the standardized broth culture (0.5 McFarland standards). Control wells contained broth and bacteria without the compound, broth with 80% methanol, and broth plus the compound without bacteria. The plates were incubated aerobically at 35°C for 24 h. MIC was taken as the lowest concentration of the compound that resulted in complete inhibition (visible turbidity) of bacterial growth. A loopful of fluid from those wells showing no growth was subcultured onto Mueller-Hinton plates for aerobic incubation to test for viability, and the lowest concentration of the compound that demonstrated no viability represented the MBC of that compound.
4.4 X-ray diffraction structure determination of 7n
Yellow block crystals were grown slowly during 1 week from a dilute solution of 7n in ethanol. A suitable crystal with approximate dimensions of 0.12 × 0.08 × 0.02 mm3 was mounted with epoxy glue on a glass fiber. Data were collected at room temperature (293 K) using an Oxford Xcalibur diffractometer. Data were acquired and processed using CrysAlisPro software [33]. Cell parameters were determined and refined using CrysAlisPro [33]. A multiscan absorption collection was applied with maximum and minimum transmission factors of 1.000 and 0.797, respectively. The structure was solved by Direct Methods and refined by full-matrix least squares on F2 using all unique data using Shelxtl [34–36]. All nonhydrogen atoms were refined anisotropically with the hydrogen atoms placed on the calculated positions using a riding model. A summary of the crystallographic data is given in Table 1.
CCDC 1453328 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
Acknowledgment
We wish to thank the Deanship of Scientific Research at The University of Jordan, Amman-Jordan, for financial support.
References
[1] A. W. Schmidt, K. R. Reddy, H.-J. Knölker, Chem. Rev. 2012, 112, 3193.10.1021/cr200447sSearch in Google Scholar
[2] D. P. Chakraborty, B. K. Barman, P. K. Bose, Tetrahedron1965, 21, 681.10.1016/S0040-4020(01)82240-7Search in Google Scholar
[3] P. Bhattacharyya, D. P. Chakraborty, Phytochemistry1973, 12, 1831.10.1016/0031-9422(73)80423-6Search in Google Scholar
[4] N. M. Cuong, T. Q. Hung, T.V. Sung, W. C. Taylor, Chem. Pharm. Bull. 2004, 52, 1175.10.1248/cpb.52.1175Search in Google Scholar
[5] K. C. Das, D. P. Chakraborty, P. K. Bose, Experientia1965, 21, 340.10.1007/BF02144703Search in Google Scholar
[6] A. Chakraborty, C. Saha, G. Podder, B. K. Chowdhury, P. Bhattacharrya, Phytochemistry1995, 38, 787.10.1016/0031-9422(94)00666-HSearch in Google Scholar
[7] A. Chakraborty, B. K. Chowdhury, P. Bhattacharrya, Phytochemistry1995, 40, 295.10.1016/0031-9422(95)00047-BSearch in Google Scholar
[8] P. Bhattacharyya, P. K. Chakraborty, B. K. Chowdhury, Phytochemistry1985, 24, 882.10.1016/S0031-9422(00)84922-5Search in Google Scholar
[9] B. Kongkathip, N. Kongkathip, A. Sunthitikawinsakul, C. Napaswat, C. Yoosook, Phytother. Res. 2005, 19, 728.10.1002/ptr.1738Search in Google Scholar PubMed
[10] D. J. Hook, J. J. Yacobucci, S. O’Connor, M. Lee, E. Kerns, B. Krishnan, J. Matson, G. Hesler, J. Antibiot. 1990, 43, 1347.10.7164/antibiotics.43.1347Search in Google Scholar PubMed
[11] S. Goodwin, A. F. Smith, E. C. Horning, J. Am. Chem. Soc. 1959, 81, 1903.10.1021/ja01517a031Search in Google Scholar
[12] R. B. Woodward, G. A. Lacobucci, F. A. Hochstein, J. Am. Chem. Soc. 1959, 81, 4434.10.1021/ja01525a085Search in Google Scholar
[13] K. Fang, S.-P. Chen, C.-W. Lin, W.-C. Cheng, H.-T. Huang, Lung Cancer2009, 63, 227.10.1016/j.lungcan.2008.05.026Search in Google Scholar
[14] M. Sainbury in Chemistry of Antitumour Agents (Ed.: D. E. V. Wilman), Blackie, Glasgow and London, 1990.Search in Google Scholar
[15] G. W. Gribble in The Alkaloids, Vol. 39 (Ed.: A. Brossi), Academic Press, New York, 1990.Search in Google Scholar
[16] C. Auclair, Arch. Biochem. Biophys. 1987, 259, 1.10.1016/0003-9861(87)90463-2Search in Google Scholar
[17] R. J. Abdel-Jalil, E. Q. El-Momani, M. Hamad, W. Voelter, M. S. Mubarak, B. H. Smith, D. G. Peters, Monatsh. Chem. 2010, 141, 251.10.1007/s00706-009-0241-4Search in Google Scholar
[18] A. Y. Habashneh, M. M. El-Abadelah, M. A. Zihlif, A. Imraish, M. O. Taha, Arch. Pharm. Chem. Life Sci. 2014, 347, 415.10.1002/ardp.201300326Search in Google Scholar PubMed
[19] R. R. Phillips, Org. React. 1959, 10, 143.10.2307/3498339Search in Google Scholar
[20] H.-C. Yao, P. Resnick, J. Am. Chem. Soc. 1962, 84, 3514.10.1021/ja00877a018Search in Google Scholar
[21] G. C. Barrett, M. M. El-Abadelah, M. K. Hargreaves, J. Chem. Soc.C1970, 1986.10.1039/J39700001986Search in Google Scholar
[22] V. M. Neplyuev, I. M. Bazavova, M. O. Lozinskii, Zh. Org. Khim. 1989, 25, 2225.Search in Google Scholar
[23] R. N. Butler, F. L. Scott, Chem. Ind. (London) 1970, 1216.Search in Google Scholar
[24] A. F. Hegarty, J. B. Aylward, F. L. Scott, J. Chem. Soc. C1967, 2587.10.1039/j39670002587Search in Google Scholar
[25] V. A. Galishev, V. N. Chisokletov, A. A. Petrov, Zh. Obshch. Khim.1975, 45, 1695.Search in Google Scholar
[26] A. S. Shawali, C. Párkányi, J. Heterocycl. Chem. 1980, 17, 833.10.1002/jhet.5570170501Search in Google Scholar
[27] H. M. Hassaneen, H. A. H. Mousa, N. M. Abed, Heterocycles1988, 27, 695.10.3987/COM-87-4381Search in Google Scholar
[28] T. Benincori, F. Sanniclolo, J. Org. Chem. 1988, 53, 1309.10.1021/jo00241a035Search in Google Scholar
[29] E. D. Awad, M. M. El-Abadelah, S. Matar, M. A. Zhilif, R. G. Naffa, E. Q. El-Momani, M. S. Mubarak, Molecules2012, 17, 227.10.3390/molecules17010227Search in Google Scholar PubMed PubMed Central
[30] M. M. Abadleh, M. M. El-Abadelah, S. S. Sabri, Q. M. A. Abdallah, A. Nasr, M. F. El-Badawy, Lett. Org. Chem.2014, 11, 664.10.2174/1570178611666140807004701Search in Google Scholar
[31] G. A. Pankey, L. D. Sabath, Clin. Infect. Dis. 2004, 38, 864.10.1086/381972Search in Google Scholar PubMed
[32] National Committee for Clinical Laboratory Standards (NCCLS), Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standards M7-A7 and 17th informational supplement M100-S17, Vol. 27, NCCLS, Wayne (PA) 2007.Search in Google Scholar
[33] CrysAlis Pro Software System (version 1.171.35.11), Intelligent Data Collection and Processing Software for Small Molecule and Protein Crystallography, Agilent Technologies Ltd., Yarnton, Oxfordshire (U.K.) 2011.Search in Google Scholar
[34] G. M. Sheldrick, Shelxtl (version 6.10), Bruker Analytical X-ray Instruments Inc., Madison, WI (USA) 2002.Search in Google Scholar
[35] G. M. Sheldrick, Acta Crystallogr.2008, A64, 112.10.1107/S0108767307043930Search in Google Scholar PubMed
[36] G. M. Sheldrick, Acta Crystallogr. 2015, C71, 3.Search in Google Scholar
©2016 by De Gruyter
Articles in the same Issue
- Frontmatter
- In this Issue
- Adducts of urea with pyrazines
- A tetranuclear Sn(IV) 4-thiazolecarboxylate complex: synthesis, structure and catalytic behavior in the bulk ring-opening polymerization of glycolide
- One-pot multicomponent synthesis of furo[3,2-c]coumarins promoted by amino-functionalized Fe3O4@SiO2 nanoparticles
- Synthesis and antibacterial activity of N1-(carbazol-3-yl)amidrazones incorporating piperazines and related congeners
- Syntheses, crystal structures, and characterization of two Mn(II) coordination polymers with bis(4-(1H-imidazol-1-yl)phenyl)methanone ligands
- New 1,3-diaryl-5-thioxo-imidazolidin-2,4-dione derivatives: synthesis, reactions and evaluation of antibacterial and antifungal activities
- Aplicyanins – brominated natural marine products with superbasic character
- Cycloaddition reactions of 2H-1-benzothietes and 1,3,5,7-tetrathio-s-indacene-2,6-dithiones
- Single functionalization of fenestrindane and centrohexaindane at the molecular periphery
- Structure of the adducts methylthiourea: 1,4-dioxane (2:1) and 1,1-dimethylthiourea: morpholine (1:1)
- Synthesis, crystal structures, and thermal and spectroscopic properties of two Cd(II) metal-organic frameworks with a versatile ligand
- Lead flux crystal growth of Ce2Ru12P7
- Synthesis and characterization of the lead borate Pb6B12O21(OH)6
Articles in the same Issue
- Frontmatter
- In this Issue
- Adducts of urea with pyrazines
- A tetranuclear Sn(IV) 4-thiazolecarboxylate complex: synthesis, structure and catalytic behavior in the bulk ring-opening polymerization of glycolide
- One-pot multicomponent synthesis of furo[3,2-c]coumarins promoted by amino-functionalized Fe3O4@SiO2 nanoparticles
- Synthesis and antibacterial activity of N1-(carbazol-3-yl)amidrazones incorporating piperazines and related congeners
- Syntheses, crystal structures, and characterization of two Mn(II) coordination polymers with bis(4-(1H-imidazol-1-yl)phenyl)methanone ligands
- New 1,3-diaryl-5-thioxo-imidazolidin-2,4-dione derivatives: synthesis, reactions and evaluation of antibacterial and antifungal activities
- Aplicyanins – brominated natural marine products with superbasic character
- Cycloaddition reactions of 2H-1-benzothietes and 1,3,5,7-tetrathio-s-indacene-2,6-dithiones
- Single functionalization of fenestrindane and centrohexaindane at the molecular periphery
- Structure of the adducts methylthiourea: 1,4-dioxane (2:1) and 1,1-dimethylthiourea: morpholine (1:1)
- Synthesis, crystal structures, and thermal and spectroscopic properties of two Cd(II) metal-organic frameworks with a versatile ligand
- Lead flux crystal growth of Ce2Ru12P7
- Synthesis and characterization of the lead borate Pb6B12O21(OH)6